A dioxin-responsive enhancer 3' of the human CYP1A2 gene.

A dioxin-responsive enhancer 3' of the human CYP1A2 gene. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

A dioxin-responsive enhancer 3' of the human CYP1A2 gene. Abstract Text:

Steven T Okino,Linda C Quattrochi,Deepa Pookot,Mieko Iwahashi,Rajvir Dahiya,Steven T Okino,Linda C Quattrochi,Deepa Pookot,Mieko Iwahashi,Rajvir Dahiya,

The human CYP1A genes CYP1A1 and CYP1A2 are in a head-to-head orientation on chromosome 15. Both CYP1A genes and CYP1B1 are transcriptionally induced by the aryl hydrocarbon receptor (AhR), a ligand-activated transcription factor that binds 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD, dioxin). Although the TCDD-responsive enhancers for CYP1A1 and CYP1B1 are well characterized, a similar CYP1A2 enhancer has not been identified. In the human prostate cell line RWPE-1, CYP1A2 mRNA expression is dramatically induced by TCDD. Therefore, analysis of the native CYP1A2 gene in these cells can provide insight into its induction mechanism. To identify sites that may bind AhR on the CYP1A locus, we scanned 75 kilobases of chromosome 15 sequence for high-affinity AhR binding sites. We then analyzed most of the sites for TCDD-inducible AhR interaction by chromatin immunoprecipitation. As expected, the CYP1A1 and CYP1B1 enhancers bind AhR in TCDD-treated cells. It is noteworthy that we identify a region 3' of CYP1A2 that also binds AhR in response to TCDD. We cannot detect AhR binding at other sites on the CYP1A locus. In vivo footprinting demonstrates that two AhR binding sites in the CYP1A2 3' region are occupied in TCDD-treated cells. Reporter-gene studies show that these sites confer TCDD-responsiveness to a heterologous promoter. AhR also binds to the CYP1A2 3' region in TCDD-treated LS180 cells but not in HepG2 and ND-1 cells. In the latter cell lines, the CYP1A2 3' region is extensively methylated. In summary, we identify a novel TCDD-responsive enhancer for CYP1A2. We were surprised to find that this enhancer is not conserved across species and is primarily human-specific.

A dioxin-responsive enhancer 3' of the human CYP1A2 gene. Publishing Authors By Initials

ST Okino,LC Quattrochi,D Pookot,M Iwahashi,R Dahiya,ST Okino,LC Quattrochi,D Pookot,M Iwahashi,R Dahiya,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

A dioxin-responsive enhancer 3' of the human CYP1A2 gene. Journal Published:

PUBLICATION TYPE: Research Support, U.S. Gov't,

Journal: Molecular pharmacology

VOLUME: 72

Page Numbers: 1457-65

Journal Abbreviation: Mol. Pharmacol.

ISSN: 1521-0111

DAY: 4

MONTH: 09

YEAR: 2007

A dioxin-responsive enhancer 3' of the human CYP1A2 gene. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 35623

A dioxin-responsive enhancer 3' of the human CYP1A2 gene. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: A dioxin-responsive enhancer 3' of the human CYP1A2 gene. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for A dioxin-responsive enhancer 3' of the human CYP1A2 gene.

AFFILIATION: Department of Urology, San Francisco Veterans Affairs Medical Center and UCSF, 4150 Clement Street, San Francisco, CA 94121, USA.

Country: United States

AGENCY: United States NIDDK

GRANT: T32DK07790

ACRONYM: DK

MEDLINETA: Mol Pharmacol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

A dioxin-responsive enhancer 3' of the human CYP1A2 gene Related Publications

• A dioxin-responsive enhancer 3' of the human CYP1A2 gene.
• Basal cell carcinoma with pulmonary and lymph node metastasis causing death.
• COD and BOD removal from domestic wastewater generated in decentralised sectors.
• COMT polymorphisms affecting protein expression are risk factors for endometrial cancer.
• CYP1A1, SULT1A1, and SULT1E1 polymorphisms are risk factors for endometrial cancer susceptibility.
• Chromatin changes on the GSTP1 promoter associated with its inactivation in prostate cancer.
• DNA methylation and histone modifications cause silencing of Wnt antagonist gene in human renal cell carcinoma cell lines.
• Effect of delignification pretreatment and selective enrichment on methane production from cattle waste.
• Epigenetic modifications of RASSF1A gene through chromatin remodeling in prostate cancer.
• Erythematous pedunculated papule on a 29-year-old man--quiz case.
• GGC and StuI polymorphism on the androgen receptor gene in endometrial cancer patients.
• Genistein down-regulates androgen receptor by modulating HDAC6-Hsp90 chaperone function.
• Genistein induces the p21WAF1/CIP1 and p16INK4a tumor suppressor genes in prostate cancer cells by epigenetic mechanisms involving active chromatin modification.
• Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells.
• Knockdown of astrocyte-elevated gene-1 inhibits prostate cancer progression through upregulation of FOXO3a activity.
• MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
• MicroRNA-373 induces expression of genes with complementary promoter sequences.
• Mismatch Repair Gene MSH3 Polymorphism is Associated With the Risk of Sporadic Prostate Cancer.
• Polymorphisms of DNA repair genes are risk factors for prostate cancer.
• Polymorphisms of catechol-O-methyltransferase in men with renal cell cancer.
• Synthesis of a phenylalanine-rich peptide as potential anthelmintic and cytotoxic agent.
• Total synthesis and biological potential of psammosilenin a.
• Transformation of Progesterone by Traemetes hispida.
• Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA.